Alternatively, NRF2 activation is attained by p62/sequestome 1 (SQSTM1)/Keap1 or p21Cip1/WAF1/Keap1 interaction [7,8], as well as by inactivating mutations on the KEAP1 gene or gain-of-function mutations on the NRF2 gene (NFE2L2) [3], although genetic alterations of KEAP1 or NFE2L2 are rare in CRC. This evidence concerns the gene CDKN1A and colorectal carcinoma.